Uveal melanoma is the most common primary malignant tumour of intraocular malignancy, arises from melanocytes in the iris, and ciliary body. The most common symptoms of uveal carcinoma include blurred vision, photopsia, visual field loss, visible tumour, pain, and metamorphopsia. The management of uveal melanoma can be divided into globe-preserving therapy or enucleation. Globe-preserving therapies can broadly classified into radiation, surgical, and laser therapy. The drug candidates of uveal melanoma disease pipeline include, but not limited to, nivolumab and IMCgp100. Some of the companies having drugs in the uveal melanoma therapeutics pipeline includes Harmonic Pharma, Immunocore Ltd. and Celldex Therapeutics, Inc.
-
The report provides a comprehensive understanding of the pipeline activities covering all drug candidates under various stages of development, with the detailed analysis of pipeline and clinical trials.
-
Pipeline analysis of drugs by phases includes product description and development activities including information about clinical results, designations, collaborations, licensing, grants, technology, and others.
